dan 2163 has been researched along with Alzheimer Disease in 11 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Model predictions were used to simulate dose-response and dose-EPS." | 1.46 | A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Dunn, JT; Greaves, S; Howard, R; Kessler, R; Marsden, P; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D; Uchida, H, 2017) |
| "Current prescribing guidelines for the antipsychotic amisulpride are based largely on pharmacokinetic (PK) studies in young adults, and there is a relative absence of data on older patients, who are at greatest risk of developing adverse events." | 1.43 | A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Greaves, S; Howard, R; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Kucwaj-Brysz, K | 1 |
| Baltrukevich, H | 1 |
| Czarnota, K | 1 |
| Handzlik, J | 1 |
| Molobekova, CA | 1 |
| Kondaurova, EM | 1 |
| Ilchibaeva, TV | 1 |
| Rodnyy, AY | 1 |
| Stefanova, NA | 1 |
| Kolosova, NG | 1 |
| Naumenko, VS | 1 |
| Boyanova, ST | 1 |
| Lloyd-Morris, E | 1 |
| Corpe, C | 1 |
| Rahman, KM | 1 |
| Farag, DB | 1 |
| Page, LK | 1 |
| Wang, H | 1 |
| Fleckney, AL | 1 |
| Gatt, A | 1 |
| Troakes, C | 1 |
| Vizcay-Barrena, G | 1 |
| Fleck, R | 1 |
| Reeves, SJ | 1 |
| Thomas, SA | 1 |
| Reeves, S | 5 |
| McLachlan, E | 4 |
| Bertrand, J | 4 |
| D'Antonio, F | 3 |
| Brownings, S | 5 |
| Nair, A | 4 |
| Greaves, S | 5 |
| Smith, A | 4 |
| Taylor, D | 4 |
| Dunn, J | 2 |
| Marsden, P | 4 |
| Kessler, R | 4 |
| Howard, R | 5 |
| Eggleston, K | 1 |
| Cort, E | 1 |
| Dunn, JT | 2 |
| Uchida, H | 1 |
| Clark-Papasavas, C | 1 |
| Mogg, A | 1 |
| Gomes, R | 1 |
| Liu, K | 1 |
| Nwosu, B | 1 |
| Joemon, J | 1 |
| Cleij, M | 1 |
| Seeman, P | 1 |
| Mauri, M | 1 |
| Mancioli, A | 1 |
| Rebecchi, V | 1 |
| Corbetta, S | 1 |
| Colombo, C | 1 |
| Bono, G | 1 |
| Lim, HK | 1 |
| Pae, CU | 1 |
| Lee, C | 1 |
| Lee, CU | 1 |
1 review available for dan 2163 and Alzheimer Disease
| Article | Year |
|---|---|
Chemical update on the potential for serotonin 5-HT
Topics: Alzheimer Disease; Animals; Humans; Nootropic Agents; Receptors, Serotonin; Serotonin Antagonists; S | 2021 |
3 trials available for dan 2163 and Alzheimer Disease
| Article | Year |
|---|---|
Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Dopamine | 2017 |
Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Anxiety D | 2006 |
Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; | 2006 |
7 other studies available for dan 2163 and Alzheimer Disease
| Article | Year |
|---|---|
Amisulpride Decreases Tau Protein Hyperphosphorylation in the Brain of OXYS Rats.
Topics: Alzheimer Disease; Amisulpride; Animals; Brain; Disease Models, Animal; Drug Inverse Agonism; Hippoc | 2023 |
Interaction of amisulpride with GLUT1 at the blood-brain barrier. Relevance to Alzheimer's disease.
Topics: Alzheimer Disease; Amisulpride; Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Sub | 2023 |
Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Female; Humans; Male; | 2018 |
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Basal Ganglia Diseases; Brain; Delusions; D | 2017 |
Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Map | 2014 |
Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease.
Topics: Alzheimer Disease; Amisulpride; Antipsychotic Agents; Benzamides; Brain Mapping; Female; Humans; Mal | 2014 |
A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Antipsychotic Agents; Female; Healthy Volun | 2016 |